Pristiq (Tablet, Extended Release)

Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/218

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
rdfs:label
Pristiq (Tablet, Extended Release)
dailymed-instance:activeIng...
dailymed-instance:boxedWarn...
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS: Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Pristiq or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Pristiq is not approved for use in pediatric patients [ see Warnings and Precautions (5.1), Use in Specific Populations (8.4), and Patient Counseling Information (17.1)].
dailymed-instance:activeMoi...
dailymed-instance:inactiveI...
dailymed-instance:genericMe...
Desvenlafaxine succinate
dailymed-instance:fullName
Pristiq (Tablet, Extended Release)
dailymed-instance:represent...
dailymed-instance:routeOfAd...
dailymed-instance:name
Pristiq